MHRA Crackdown on Illegal Botox Products – What Practitioners Need to Know
The MHRA (Medicines and Healthcare products Regulatory Agency) has issued a press release following a rise in cases of botulism linked to unlicensed botulinum toxin products being used in the UK.
Between June and August 2025, 41 confirmed cases of botulism were reported across several regions of England. Investigations suggest these were caused by unlicensed products administered in unregulated and unsafe settings.
Key Facts for Practitioners
-
Botulinum toxin is a prescription-only medicine (POM). It should only be prescribed and administered by a qualified healthcare professional.
-
Since May 2023, the MHRA and Border Force have seized more than 4,700 vials of unlicensed products, many from overseas brands not authorised for sale in the UK (including Botulax, reNTox, Innotox, and Toxpia).
-
The MHRA has warned that anyone supplying or using unlicensed botulinum toxin faces up to two years in prison and unlimited fines under UK law.
Risks Highlighted by MHRA
-
Botulism is rare but potentially life-threatening, causing paralysis, breathing difficulties, and in some cases requiring intensive care.
-
Symptoms may take up to four weeks to develop.
-
Patients who experience difficulty swallowing, slurred speech, or breathing issues after treatment should be directed to seek immediate medical help via NHS 111 or emergency services.
Guidance from MHRA
The MHRA is advising that:
-
Only licensed products should ever be used in treatments.
-
Practitioners must ensure that treatments are carried out in a clinical setting with appropriate hygiene and emergency protocols in place.
-
Cheap offers, informal settings, or products without UK authorisation should be treated as red flags.
What This Means for Your Practice
This enforcement action reinforces the importance of:
-
Using UK-licensed products only – never unlicensed or imported toxins.
-
Maintaining robust record-keeping (batch numbers, product packaging, patient consent).
-
Prioritising patient safety – ensuring treatments are conducted in safe environments, with access to emergency medicines and equipment.
-
Educating patients who may see cheaper options online or via social media about the risks of unsafe products.
Our Commitment to You
At Derma Direct, although we do not supply toxin products, we only supply licensed, authorised products sourced through regulated supply chains. We know that, for practitioners, patient safety always comes first, and we are committed to supporting you with reliable, compliant products you can trust.
Click here to read the full article by the MHRA.
